MediXall Group, Inc.
MDXL
$0.0035
$0.00026.06%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 421.75% | 296.57% | 239.39% | 559.69% | 295.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 421.75% | 296.57% | 239.39% | 559.69% | 295.33% |
| Cost of Revenue | -61.17% | -62.23% | -63.47% | -49.11% | 4.30% |
| Gross Profit | 70.30% | 69.32% | 69.15% | 52.11% | -2.86% |
| SG&A Expenses | -11.27% | 2.74% | 5.60% | -5.12% | 0.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -993.94% | -993.94% | -993.94% | -993.94% |
| Total Operating Expenses | -33.77% | -35.69% | -35.95% | -30.87% | -0.02% |
| Operating Income | 38.04% | 40.13% | 39.73% | 32.42% | 0.71% |
| Income Before Tax | 33.19% | 28.76% | 29.36% | 22.49% | -10.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.19% | 28.76% | 29.36% | 22.49% | -10.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.19% | 28.76% | 29.36% | 22.49% | -10.16% |
| EBIT | 38.04% | 40.13% | 39.73% | 32.42% | 0.71% |
| EBITDA | 38.21% | 40.67% | 40.25% | 32.91% | 1.25% |
| EPS Basic | 37.58% | 33.07% | 33.53% | 28.02% | 0.81% |
| Normalized Basic EPS | 37.01% | 39.69% | 39.56% | 33.72% | 7.33% |
| EPS Diluted | 31.00% | 31.35% | 35.02% | 34.89% | 11.42% |
| Normalized Diluted EPS | 37.01% | 39.69% | 39.56% | 33.72% | 7.33% |
| Average Basic Shares Outstanding | 9.43% | 9.68% | 9.32% | 10.27% | 12.27% |
| Average Diluted Shares Outstanding | 9.43% | 9.68% | 9.32% | 10.27% | 12.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
